Biosimilars Players Climb Global Rankings
Final Part Of Top 50 Ranking Sees Biosimilars Specialists Making Progress
Executive Summary
Biosimilars players are gaining an increasing foothold in the off-patent industry, as demonstrated by the final part of our annual Top 50 ranking.
You may also be interested in...
Ipca Takes Full Ownership Of Bayshore
Ipca has struck a deal to take full ownership of US firm Bayshore Pharmaceuticals by acquiring the remaining 20% stake that it did not already own.
Lupin Seeks Partners For Biosimilars And Oncology Research
Buoyed by a $50m milestone payment for a MEK inhibitor licensed to Boehringer Ingelheim and in a bid to mitigate the burn on profits, Lupin is considering partnerships for biosimilars, specialty products and other NCEs with recently spun-off oncology assets being first in line for a deal. But FY22 earnings guidance has been lowered.
Lupin Seeks Partners For Biosimilars, Oncology Research
Buoyed by a $50m milestone payment for a MEK inhibitor licensed to Boehringer Ingelheim and in a bid to mitigate the burn on profits, Lupin is considering partnerships for biosimilars, specialty products and other NCEs with recently spun-off oncology assets being first in line for a deal. But FY22 earnings guidance has been lowered.